Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Strs Ohio

Strs Ohio decreased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 3.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,900 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the period. Strs Ohio’s holdings in Dynavax Technologies were worth $865,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System bought a new stake in shares of Dynavax Technologies in the 4th quarter worth $905,000. Executive Wealth Management LLC bought a new stake in Dynavax Technologies in the fourth quarter worth about $280,000. Allspring Global Investments Holdings LLC lifted its holdings in Dynavax Technologies by 185.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 118,074 shares of the biopharmaceutical company’s stock valued at $1,651,000 after acquiring an additional 76,728 shares during the last quarter. Wakefield Asset Management LLLP bought a new position in shares of Dynavax Technologies during the 4th quarter valued at about $828,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dynavax Technologies by 7.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,116 shares of the biopharmaceutical company’s stock worth $1,218,000 after purchasing an additional 6,296 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Performance

Shares of DVAX opened at $11.42 on Thursday. The company has a 50-day moving average of $12.28 and a two-hundred day moving average of $13.23. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -190.30 and a beta of 1.26. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96. Dynavax Technologies Co. has a one year low of $10.06 and a one year high of $15.15.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.98% of the stock is owned by insiders.

Analyst Ratings Changes

DVAX has been the subject of a number of research reports. The Goldman Sachs Group assumed coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They set a “neutral” rating and a $20.00 target price for the company. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Finally, StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.